Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration

US11040019B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Wenxin Ma · Potomac, US
• Lian Zhao · Kensington, US
• Xu Wang · 安丰镇, CN
• Wai T. Wong · Philadelphia, US

Key dates

• Filing date: Aug 10, 2017
• Grant date: Jun 22, 2021
• Expiry date: Jan 6, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P27/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods are disclosed for treating and/or preventing retinal degeneration is a subject. In some embodiments, the method includes administering to the subject a therapeutically effective amount of a selective estrogen receptor modulator (SERM) to treat the retinal degeneration in the subject. In other embodiments, the SERM is administered orally. In some examples, the SERM is tamoxifen, afimoxifene, raloxifene, bazedoxifene, arzoxifene, desmethylarzoxifene, or a salt or derivative thereof, or combinations thereof.